Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data
Following 12 weeks of treatment, Recursion said, 87% of patients (13 of 15) had a reduction in total polyp burden, with a 47% median reduction. Approximately one in three patients achieved reductions of ≥65%. The post Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data appeared first on GEN - Genetic Engineering and Biotechnology News .
Recursion anticipates launching its first registrational trial in the second half of 2027 for its lead candidate REC-4881, following positive mid-stage clinical data from the Phase Ib/II TUPELO trial. The trial, which generated encouraging results, demonstrated reductions in both larger, higher-risk polyps and lower GI polyp burden in most patients treated with REC-4881.
This oral therapy represents a significant advancement in the treatment of familial adenomatous polyposis (FAP), a rare genetic disorder that currently has no approved pharmacologic therapies. REC-4881 is a first-in-class, oral allosteric inhibitor of MEK1 and MEK2, and its development was facilitated through a global licensing agreement with Takeda Pharmaceutical.
The drug's anticipated second half 2027 timing for a registrational trial will depend on discussions with the FDA.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
